title: Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
abstract: Between August 1985 and April 1989, 88 patients (31 children and 57 adults) with refractory of relapsed acute lymphoblastic leukemia (ALL) were treated in a cooperative Italian trial by an induction schedule of high-dose Cytarabine (HDAra-C) plus Idarubicin (IDA). Complete remission (CR) was achieved in 52 of the 88 patients (59%); 23 patients (26%) did not respond to treatment and 13 (15%) died during induction. The CR rate was significantly affected by the WBC count at the beginning of treatment and by the duration of first CR of the patients treated at first relapse. All of the patients experienced profound myelosuppression; the median time to recovery to neutrophils greater than 0.5 x 10(9)/l was 15 days (range 4-40), and 14 days (range 3-50) to platelets greater than 50 x 10(9)/l. The most common non-hematologic side effects observed were nausea and vomiting (51%), mucositis (40%) and diarrhea (23%). Twenty-one of the 52 patients who achieved CR underwent bone marrow transplantation (BMT), 16 autologous and 5 allogeneic. Eleven patients relapsed at a median of 4 months (range 1-31) after the transplantation, and three patients died while in CR. Seven patients have been in continuous CR (CCR) for a median of 36 months (range 26-42 months). Thirty-one patients were not entered in the BMT program: for two adults it was too early, three adults died in CR and 25 patients relapsed at a median of four months (range 1-25). Only one adult is still in CCR at 33 months.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Ematologia, Dipartimento di Biopatologia Umana, Università degli Studi La Sapienza, Roma, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Giona
authors.forename: A M
authors.initials: AM
authors.lastname: Testi
authors.forename: S
authors.initials: S
authors.lastname: Amadori
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: M
authors.initials: M
authors.lastname: Carotenuto
authors.forename: L
authors.initials: L
authors.lastname: Resegotti
authors.forename: R
authors.initials: R
authors.lastname: Colella
authors.forename: P
authors.initials: P
authors.lastname: Leoni
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: P
authors.initials: P
authors.lastname: Grotto
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D007223:Infant; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012008:Recurrence
chemical_list: D003561:Cytarabine; D015255:Idarubicin